Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO

On April 28, 2022 Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that two ONCOS-102 abstracts have been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago 3-7 June 2022 (Press release, Targovax, APR 28, 2022, View Source [SID1234613093]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts will be released on the ASCO (Free ASCO Whitepaper) website 26 May 17:00 CEST (View Source). The posters are scheduled for presentation during the ASCO (Free ASCO Whitepaper) congress 3 – 7 June 2022.

Poster title: Final survival outcomes and immune biomarker analysis of a randomized, open-label, phase I/II study combining oncolytic adenovirus ONCOS-102 with pemetrexed/cisplatin (P/C) in patients with unresectable malignant pleural mesothelioma (MPM)
Presenter: Dr Santiago Ponce, Medical Oncology, Hospital 12 Octubre, Madrid, Spain
Poster title: Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results
Presenter: Dr Dmitriy Zamarin, Memorial Sloan Kettering Cancer Center, New York, USA

About ASCO (Free ASCO Whitepaper)

American Society of Clinical Oncology Annual Meeting, ASCO (Free ASCO Whitepaper) 2022 will be held in McCormick Place, Chicago, Illinois, United States between 03 – 07 June 2022.

The 2022 ASCO (Free ASCO Whitepaper) Annual Meeting Program will offer presentations on the latest research in cancer care. This year’s program will feature sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.